Generally speaking, most manufacturers aim to spruce up the appearance of a volume seller every three years or so - otherwise ...

In today's Pharmaceutical Executive Daily, Vertex Pharmaceuticals announces a $10 billion acquisition of Crinetics ...

An announcement from Crinetics Pharmaceuticals ( (CRNX)) is now available. On July 6, 2026, Vertex Pharmaceuticals and Crinetics Pharmaceuticals signed a definitive merger agreement under which Vertex ...

The Boston-based drugmaker has been on a mission to build out the next generation of drug products beyond its cystic fibrosis ...

Find insight on Eli Lilly, Vertex Pharmaceuticals and more in the latest Market Talks covering the health care sector.

The S&P/ASX 200 is set to fall after oil prices spiked on renewed US-Iran tensions. Here are today's top stories.

Major indexes declined Tuesday, pulled lower by chip stocks, after beginning the week with gains. The Dow Jones Industrial ...

Casgevy is now approved in the U.S. for children with sickle cell as young as 2, becoming the first gene-editing therapy for ...

On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing ...

CRNX surges on Vertex’s $10B deal, FISV rises on STAR sale talks, RIVN drops on offering, MU slips on glut fears—read more.

Q2 of 2026 started with a white-hot rally in the stock market, recovering its losses from the first quarter and setting ...

The roller-coaster ride for AI stocks is snapping lower again Tuesday and weighing on Wall Street. The S&P 500 fell 0.6% even ...